This study plans to learn more about how safe the investigational study drug CB-03-10 is, and to see how your body tolerates CB-03-10 and how your body reacts to the drug
This study has 2 parts. Part 1 is also called Dose Escalation. During Part 1 groups of patients with cancer, also known as cohorts, will take different doses of the study drug and be followed closely. At the end of the Part 1 of the study, we will see what dose of the study drug is tolerable and may be used in the second part of the study. Part 2 is also called Dose Expansion. During Part 2, patients with types of cancer most likely to respond to the study drug will take the dose recommended based on Part 1 of the study. You may be enrolled either in Part 1 or Part 2 of the study, depending on which part of the study is open at the time you enroll.
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.
Principal Investigator